ClinicalTrials.gg
RecruitingNCT04513808Updated Sep 8, 2026

Total Intravenous Anesthesia and Recurrence Free Survival

A Phase 3 interventional study of Propofol-based total intravenous anesthesia and Sevoflurane intravenous anesthesia in Esophageal Cancer, sponsored by The Cleveland Clinic. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by The Cleveland Clinic · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,614
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.

Planned enrollment
14th of 394
1,614 · median 80
Started
2020
with 25 others
Phase 3
62 of 502
20 open now
Primary completion
2026-12
later than 134 of 237 live
Registered
201st of 502
by date

Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 14th largest by planned enrollment of the 394 interventional ones that give a count, is one of 26 that started in 2020, is one of 62 in phase 3, reaches primary completion later than 134 of the 237 other live ones, and was the 201st registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Esophageal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.

Read the detailed description

The investigators will test the primary hypothesis that recurrence-free survival after esophageal cancer surgery is longer in patients randomized to propofol-based total intravenous anesthesia than to volatile sevoflurane anesthesia.

The investigators will test the secondary hypotheses that propofol-based total intravenous anesthesia: 1) speeds discharge from the ICU; 2) speeds discharge from the hospital; and, 3) improves the quality of recovery, as assessed by QoR-15 on postoperative day 2.

03

Conditions studied

  • Esophageal Cancer
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary esophageal cancer without known extension beyond the esophagus. (i.e. believed to be Tumor Stage 1-3).
  • Scheduled for potentially curative esophageal cancer surgery.
  • Written , including willingness to be randomized to intravenous versus volatile anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Previous surgery for esophageal cancer (except diagnostic ) Age \<18 or >85 years old.
  • ASA Physical Status ≥4.
  • Any to propofol or sevoflurane.
  • Other cancer not believed by the attending surgeon to be in long-term remission.
  • Systemic disease believed by the attending surgeon to present ≥25% two- year mortality.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
1,614 participants (estimated)

Study arms

  • Active comparator
    Propofol-based total intravenous anesthesia

    Propofol-based total intravenous anesthesia. A target-controlled infusion will be set to 2-4 µg/ml plasma concentrations, and varied as clinical necessary.

    Drug: Propofol-based total intravenous anesthesia

  • Active comparator
    Sevoflurane intravenous anesthesia

    Anesthesia will be maintained with sevoflurane, typically at an end-tidal concentration of 0.6-1.0 MAC, but adjusted as clinically necessary

    Drug: Sevoflurane intravenous anesthesia

Interventions

  • DrugPropofolStudies of PropofolPropofol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Propofol-based total intravenous anesthesia, titrated to clinical need.

    Also known as: Propofol

  • DrugSevofluraneStudies of SevofluraneSevoflurane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sevoflurane intravenous anesthesia, titrated to clinical need.

    Also known as: Sevoflurane

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival

    Patients who did not experience cancer recurrence and/or death.

    Time frame: 4 years

Secondary outcomes

  1. ICU duration

    Postoperative time in ICU during initial admission.

    Time frame: From ICU admission until the date of ICU discharge or date of death from any cause, whichever came first, assessed up to 100 months

  2. Hospital duration

    Postoperative time spent in hospital during initial admission.

    Time frame: Up to 100 months

  3. QoR-15

    Quality of Recovery 15 score on postoperative day 2.

    Time frame: 2 days

07

Study locations

1 of 1 sites recruiting
  • Shanhai Chest Hospital
    Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared collaboratively with appropriate approvals and contracts.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: 2 years after publication of the main paper.

Access criteria: Contact investigators.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.

Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's planned 76 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2020
First posted
Aug 14, 2020
StartActual
Aug 15, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04513808
Responsible party
Sponsor
First posted
Aug 14, 2020
Start date
Aug 15, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Yuwei Qiu, MD
Contact
qiuyuweixk@163.com
86 21 6282 1990
Yuwei Qiu, MD
principal investigator · Shahai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Propofol · Sevoflurane

Start the discussion